These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 33607854)

  • 1. The effects of teriparatide and bisphosphonates on new fractures in postmenopausal women with osteoporosis: A protocol for systematic review and meta-analysis.
    Ouyang Y; Chen S; Wan T; Zheng G; Sun G
    Medicine (Baltimore); 2021 Feb; 100(7):e24839. PubMed ID: 33607854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis.
    Yuan F; Peng W; Yang C; Zheng J
    Int J Surg; 2019 Jun; 66():1-11. PubMed ID: 30890377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients: A meta-analysis.
    Fan G; Zhao Q; Lu P; Chen H; Tan W; Guo W; Liu C; Liu J
    Medicine (Baltimore); 2020 Apr; 99(15):e18964. PubMed ID: 32282692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
    Ayers C; Kansagara D; Lazur B; Fu R; Kwon A; Harrod C
    Ann Intern Med; 2023 Feb; 176(2):182-195. PubMed ID: 36592455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates in multiple myeloma: an updated network meta-analysis.
    Mhaskar R; Kumar A; Miladinovic B; Djulbegovic B
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003188. PubMed ID: 29253322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials.
    Wang YK; Qin SQ; Ma T; Song W; Jiang RQ; Guo JB; Li K; Zhang YM
    Medicine (Baltimore); 2017 May; 96(21):e6970. PubMed ID: 28538396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
    Albert SG; Reddy S
    Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates for steroid-induced osteoporosis.
    Allen CS; Yeung JH; Vandermeer B; Homik J
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD001347. PubMed ID: 27706804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
    Hara T; Hijikata Y; Matsubara Y; Watanabe N
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013424. PubMed ID: 34231877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis.
    Serrano AJ; Begoña L; Anitua E; Cobos R; Orive G
    Gynecol Endocrinol; 2013 Dec; 29(12):1005-14. PubMed ID: 24063695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05.
    Hagino H; Sugimoto T; Tanaka S; Sasaki K; Sone T; Nakamura T; Soen S; Mori S
    Osteoporos Int; 2021 Nov; 32(11):2301-2311. PubMed ID: 34002252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
    Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
    Wells GA; Cranney A; Peterson J; Boucher M; Shea B; Robinson V; Coyle D; Tugwell P
    Cochrane Database Syst Rev; 2008 Jan; (1):CD001155. PubMed ID: 18253985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women.
    Ellis AG; Reginster JY; Luo X; Bushmakin AG; Williams R; Sutradhar S; Mirkin S; Jansen JP
    Curr Med Res Opin; 2014 Aug; 30(8):1617-26. PubMed ID: 24773456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
    Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
    Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
    Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
    Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
    N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.